Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Improved adalimumab dose decision with comprehensive diagnostics data
Filename | 300. Zänker et al., Adalimumab. ClinExpRheum 2018.pdf |
Version | o.300 |
Date added | July 28, 2020 |
Downloaded | 0 times |
Category | Original Work |
Tags | adalimumab, recoveryELISA, rheumatoid arthritis, therapeutic antigen monitoring, therapeutic drug monitoring |
Authors | Zänker, M., Becher, G., Arbach, O., Maurer, M. Stuhlmüller, B., Schäfer, A., and Strohner, P. |
Citation | Zänker, M., Becher, G., Arbach, O., Maurer, M. Stuhlmüller, B., Schäfer, A., and Strohner, P.: Improved adalimumab dose decision with comprehensive diagnostics data. Clin. Exp. Rheumatol. 2018: 36; 136-139. |
Corresponding authors | Zänker, M. |
DocNum | O.300 |
DocType | |
Edition; Page | 36; 136-139. |
IF | 3.20 |
Publisher | Clin. Exp. Rheumatol. |
ReleaseDate | 2018 |
Objective: Monoclonal antibodies are important in the treatment of rheumatoid arthritis (RA). This is the first trial to monitor the effect of adalimumab dose escalation in persistently active RA. The aim of this study was to identify the response to adalimumab to improve the basis for making decision in rela-tion to actual drug capacity in serum.
Methods: The disease activity of RA patients was assessed with CDAI and DAS28 before administration of additional 40 mg adalimumab one week after standard injection. Serum samples were analysed using the recoveryELI-SA technology, a combination of sand-wich ELISA and competitive assay. The recoveryELISA measure the concentra-tions of free TNF-α, drug level, and the remaining active adalimumab in the patients’ sera. An adalimumab concen-tration of 5.0–10.0 g/mL was defined as the targeted therapeutic window.
Results: Five of 8 patients achieved moderate EULAR response by dose escalation. The results of the free adalimumab and TNF-α neutralisation measurements allowed a separation of the cohort (n=17) into three groups. Group 1 represents 18% of the patients with free adalimumab level higher 30.0 μg/mL and TNF-α neutralisation above 95%. Group 2 (47%) consists of pa-tients within the therapeutic window with balanced free adalimumab and TNF-α neutralisation values. Group 3 contains 35% of the cohort with low concentrations of free adalimumab and lowest remaining TNF-α-neutralisation capacity. Anti-drug antibodies were de-tected in four patients but did not pre-vent response to treatment.
Conclusion: Drug and antigen monitoring using recoveryELISA may sup-port dose decision to avoid unnecessary switch in medication or possible overtreatment.
(Last update: 09.2024)
Number of original publications in peer-reviewed journals: | 626 |
Number of reviews in peer-reviewed journals: | 221 |
Number of publications (original work and reviews) in peer-reviewed journals: | 847 |
Cumulative IF for original publications in peer-reviewed journals: | 4432.59 |
Cumulative IF for reviews in peer-reviewed journals: | 1648.22 |
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 6080.81 |
Total number of citations: 38,608, h-index: 99 (Web of Science September 2024) | 38,608 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.